drugset / Trial / NCT07706166
Letermovir for R+ Study
Phase 4
Not yet recruiting
146 enrolled
University of Wisconsin, Madison
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
Timeline
- Start
- 2026-10
- Primary completion
- 2029-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | — | Oral |
Indications
No indication recorded.